Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

29.22USD
23 Feb 2018
Change (% chg)

$0.62 (+2.17%)
Prev Close
$28.60
Open
$28.57
Day's High
$29.26
Day's Low
$28.25
Volume
89,551
Avg. Vol
139,616
52-wk High
$29.26
52-wk Low
$11.44

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $792.65
Shares Outstanding(Mil.): 36.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

18 Dec 2017

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

28 Nov 2017

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

07 Nov 2017

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

24 Oct 2017

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 4,752.00 -20.00
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Novartis AG (NOVN.S) CHF79.38 -0.60
Pfizer Inc. (PFE.N) $36.26 +0.52
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Sanofi SA (SASY.PA) €65.05 +0.16
ImmunoGen, Inc. (IMGN.OQ) $11.19 +0.33
Seattle Genetics, Inc. (SGEN.OQ) $55.35 +1.57

Earnings vs. Estimates